• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Halozyme Therapeutic (NQ: HALO )

    56.95 +6.38 (+12.62%)
    Streaming Delayed Price Updated: 3:03 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Halozyme Therapeutic

    < Previous 1 2 3 4 5 6 7 8 Next >
    Halozyme Therapeutics's Earnings: A Preview
    Via Benzinga
    Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review
    Sharp Tesla price cuts and some notable earnings were in focus. 
    Via Investor's Business Daily
    Nasdaq Rises Over 1%; CommVault Systems Shares Plummet
    U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Wednesday. 
    Via Benzinga
    CommVault Systems, Halozyme Therapeutics And Other Big Stocks Moving Lower On Wednesday
    U.S. stocks traded higher, with the Dow Jones gaining around 80 points on Wednesday. Here are some big stocks recording losses in today’s session. 
    Via Benzinga
    Where Halozyme Therapeutics Stands With Analysts
    Via Benzinga
    5 Analysts Have This to Say About Halozyme Therapeutics
    Via Benzinga
    4 Analysts Have This to Say About Halozyme Therapeutics
    Via Benzinga
    Halozyme Therapeutics Shares Jump On Better Than Expected Annual Guidance
    Via Benzinga
    Why Broadwind Shares Are Trading Higher By 85%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Gainers Broadwind Inc (NASDAQ: BWEN) shares climbed 85.4% to $4.19 after the company announced the receipt of approximately $175 million in new tower orders from a leading global wind turbine... 
    Via Benzinga
    US Stocks Open Higher; Nasdaq Rises 60 Points
    U.S. stocks traded higher this morning, with the Nasdaq gaining around than 600 points on Wednesday. 
    Via Benzinga
    10 Health Care Stocks Whale Activity In Today's Session
    This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
    Via Benzinga
    Stocks That Hit 52-Week Lows On Thursday
      During Thursday's session, 108 stocks hit new 52-week highs. 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For November 28, 2022
    Via Benzinga
    Argenx's Flagship Neuromuscular Treatment For Subcutaneous Injection Goes Under Priority FDA Review
    Via Benzinga
    Amazon To $103? Plus Piper Sandler Predicts $300 For Illumina
    Rosenblatt boosted the price target on Amazon.com, Inc. (NASDAQ: AMZN) from $118 to $103. Rosenblatt analyst Barton Crockett maintained the stock with a Neutral rating. Amazon shares fell 4.3% to close... 
    Via Benzinga
    Stock Market Rally Roars Higher On Cooling Inflation; Bitcoin, Meta, Tesla In Focus: Weekly Review
    Bitcoin hit a two-year low while Meta and Tesla were in focus. 
    Via Investor's Business Daily
    Stocks That Hit 52-Week Lows On Friday
      On Friday, 68 companies reached new 52-week highs. 
    Via Benzinga
    Meta Platforms, Hilton Grand Vacations, D.R. Horton, And Some Other Big Stocks Moving Higher On Wednesday
    U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Wednesday. Here are some big stocks recording gains in today’s session. 
    Via Benzinga
    Argenx Seeks FDA Nod For Its Flagship Neuromuscular Treatment Formulated For Subcutaneous Injection
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
    Upgrades 
    Via Benzinga
    10 Health Care Stocks With Whale Alerts In Today's Session
      This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
    Via Benzinga
    Halozyme Therapeutics: Q2 Earnings Insights
      Halozyme Therapeutics (NASDAQ:HALO) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
    Via Benzinga
    Biotech Daily: Trial Setback For Eliem Therapeutics, Allarity Drops Work On Cancer Monotherapies, Axcella Aces Long COVID Study
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    7 Biotech Stocks With Key Catalysts Coming in July
    Biotech stocks have had a rocky few months, but many are on the mend. These picks should provide investors both flexibility and growth. 
    Via InvestorPlace
    Cannabis Movers & Shakers: Mind Medicine, 22nd Century Group, Grown Rogue International
    Mind Medicine Names New CEO Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) has hired Schond L. Greenway to oversee its finance department. 
    Via Benzinga
    MindMed Appoints Schond L. Greenway As CFO
    Mind Medicine Inc. (NASDAQ: MNMD), (NEO:MMED), a clinical stage bio-pharmaceutical company developing novel products to treat brain health disorders, appointed Schond L. Greenway as CFO. 
    Via Benzinga
    Recap: Halozyme Therapeutics Q1 Earnings
    Halozyme Therapeutics (NASDAQ:HALO) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement. 
    Via Benzinga
    Halozyme Therapeutics's Earnings Outlook
    Halozyme Therapeutics (NASDAQ:HALO) is set to give its latest quarterly earnings report on Tuesday, 2022-05-10. Here's what investors need to know before the announcement. Analysts estimate that... 
    Via Benzinga
    Why Is Sierra Oncology (SRRA) Stock Up Today?
    Late-phase cancer treatment company Sierra Oncology is up big today after being acquired by GlaxoSmithKline. SRRA stock is soaring. 
    Via InvestorPlace
    < Previous 1 2 3 4 5 6 7 8 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.